跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 325 条关于
“H3 K27M”
全部
325
临床试验
122
药物
64
机构
1
资讯
138
去年
FDA Grants First Accelerated Approval for H3 K27M-Mutated Diffuse Midline Glioma with Dordaviprone
去年
FDA Approves Modeyso as First Treatment for Recurrent H3 K27M-Mutant Diffuse Midline Glioma
去年
Chimerix Seeks Accelerated FDA Approval for Dordaviprone in H3 K27M-Mutant Glioma
去年
Dordaviprone Shows Promise in Recurrent H3 K27M-Mutant Glioma: Updated Phase 2 Data
去年
FDA Grants Priority Review to Dordaviprone for Recurrent H3 K27M-Mutant Diffuse Glioma
去年
Chimerix's Dordaviprone Shows Promising Response in Recurrent Glioma Phase 2 Trial
4个月前
HealthCare Royalty Secures Modeyso Royalty Rights Following Strong Early Commercial Performance
去年
Jazz Pharmaceuticals to Acquire Chimerix for $935M, Gaining Novel Brain Tumor Drug Candidate
去年
Jazz Pharmaceuticals Reports Strong Q1 2025 Performance with $898 Million in Revenue, Advances Pipeline with Zepzelca sNDA Submission
13天前
FDA Grants First-Ever Approval for DIPG Treatment as Family Advocacy Fuels Research Momentum
第 1 页,共 14 页
上一页
下一页